CK Positivity and Retained E-Cadherin: Diagnostic Significance
Cytokeratin (CK) positivity combined with retained E-cadherin expression in a biopsy strongly suggests an epithelial carcinoma that has NOT undergone epithelial-mesenchymal transition (EMT), which helps narrow the differential diagnosis and typically indicates a less aggressive tumor phenotype.
Diagnostic Interpretation Framework
Primary Tumor Type Identification
When you encounter CK-positive, E-cadherin-retained tumors, work through this algorithmic approach:
Step 1: Confirm Epithelial Origin
- CK positivity confirms epithelial lineage and excludes lymphoma, melanoma, and most sarcomas 1
- Retained E-cadherin further supports epithelial differentiation and argues against mesenchymal transformation 2
Step 2: Determine Specific CK Pattern The specific cytokeratin subtype matters significantly:
- CK7+/CK20- pattern suggests: lung adenocarcinoma, breast cancer, or cholangiocarcinoma 1, 3
- CK7+/CK20+ indicates: colorectal cancer or urothelial carcinoma 1
- CK5/6 or CK14 (basal cytokeratins): mesothelioma or basal-like breast cancer 4
Step 3: Add Site-Specific Markers Based on clinical context, add:
Clinical Significance of Retained E-Cadherin
Prognostic Implications
Favorable indicators when E-cadherin is retained:
- Preserved epithelial architecture and cell-cell adhesion 2
- Lower metastatic potential compared to E-cadherin-loss tumors 6, 7
- Better response to conventional therapies in most contexts
Critical caveat: The combination of CK positivity with E-cadherin retention does NOT automatically mean good prognosis—you must integrate histologic grade, proliferation markers (Ki-67), and tumor stage 8, 9.
Specific Tumor Contexts
In breast cancer:
- Luminal subtypes typically retain E-cadherin 5, 9
- Loss of E-cadherin with CK positivity suggests lobular carcinoma or aggressive basal-like phenotype 8
- Triple-negative tumors with E-cadherin loss and high CK19/Ki-67 have worst outcomes 8
In gastric/GI adenocarcinomas:
- Well-differentiated tumors preserve E-cadherin expression 7
- E-cadherin loss correlates with lymph node metastasis, advanced stage, and perineural invasion 10, 7
- Signet ring and diffuse-type carcinomas characteristically lose E-cadherin 7
In prostate cancer:
- Conventional adenocarcinomas retain E-cadherin 11
- E-cadherin loss suggests plasmacytoid variant or CDH1 alterations—extremely aggressive phenotype 11
Common Diagnostic Pitfalls
Avoid These Errors
Don't rely on E-cadherin alone for diagnosis—it's a prognostic marker, not a lineage-specific marker 2
Mesothelioma mimicry: Epithelioid mesothelioma is CK5/6+ but typically E-cadherin negative; requires calretinin and WT-1 for confirmation 4
Solid-pseudopapillary neoplasm of pancreas: Shows nuclear β-catenin with E-cadherin LOSS despite being epithelial (CK+)—this is the diagnostic signature 12
Lymph node assessment in breast cancer: Don't use routine CK immunohistochemistry to upstage H&E-negative nodes—it doesn't improve outcomes and leads to overtreatment 13, 14
Treatment Implications
When E-Cadherin is Retained
- Standard chemotherapy regimens appropriate for the primary tumor type
- Consider less aggressive surgical approaches in early-stage disease
- Hormone therapy effective if hormone receptors present (breast, prostate)
When E-Cadherin is Lost (Despite CK Positivity)
- Anticipate higher metastatic risk 6, 7
- Consider more aggressive locoregional control
- May benefit from EMT-targeted therapies in clinical trials
- Closer surveillance protocols warranted
Cancer of Unknown Primary (CUP)
If dealing with metastatic disease of unknown origin that is CK+/E-cadherin+:
- Complete the immunohistochemical panel per ESMO guidelines 1
- Consider gene expression profiling for site-specific therapy 1
- CT chest/abdomen/pelvis mandatory 1
- Site-specific serum markers (PSA in males, CA-125 in females with peritoneal disease) 1
The combination of preserved epithelial markers (CK and E-cadherin) narrows your differential significantly and generally indicates tumors that maintain epithelial characteristics rather than undergoing aggressive EMT-driven metastasis.